In Re Regulus Therapeutics Inc. Securities Litigation

District Court, S.D. California·Decided October 30, 2020·No. 3:17-cv-00182·Unknown

Opinion

IN RE REGULUS Case No.: 3:17-cv-182-BTM-RBB THERAPEUTICS INC. Case No.: 3:17-cv-267-BTM-RBB SECURITIES LITIGATION APPROVAL OF SETTLEMENT . AND ATTORNEYS’ FEES [ECF NOS. 46, 47]

The Court previously granted a motion for preliminary approval of the parties' Class Action Settlement in this matter on May 27, 2020. (ECF No. 43.) As directed by the Court's preliminary approval order, Plaintiffs filed their unopposed motion for final settlement approval and motion for attorneys’ fees and costs. (ECF Nos. 46, 48.) The Court held a hearing on October 21, 2020. (ECF No. 52.) Having considered the motion briefing, the terms of the Settlement Agreement, the lack of any objections, the arguments of counsel, and the other matters on file in this action, the Court GRANTS the motions for final approval and attorneys’ fees and costs.

A. Procedural History Plaintiffs filed the putative class action complaint on December 21, 2017 against Defendants Regulus Therapeutics Inc., Paul C. Grint, M.D., Joseph P. Hagan, and Michael Huang, M.D., alleging Defendants made false and/or misleading statements about adverse events relating to Regulus’s signature drug RG-101, a hepatitis C treatment, in violation of the Securities Exchange Act of 1934 (“Exchange Act”). (ECF No. 1.) RG-101 was intended to cut hepatitis C treatment time in half. Plaintiffs, however, allege that Defendants downplayed or ignored a series of preclinical and nonclinical data and serious adverse events indicating that RG-101 was prone to hepatoxicity (liver toxicity), which leads to jaundice. On February 20, 2017, Plaintiff Ji Lin filed a separate suit asserting the same claims against Defendants. (Case No. 3:17-cv-267, ECF No. 1.) On October 26, 2017, the Court consolidated the two cases and appointed Levi & Korsinsky LLP as Lead Counsel and Mark Appel and Michael Spitters as Co-Lead Plaintiffs. (ECF No. 16.) Plaintiffs filed a consolidated complaint on December 12, 2017. (ECF No. 19.) On February 6, 2018, Defendants moved to dismiss the consolidated complaint. (ECF No. 22.) The Court the Court granted Defendants' motion with leave to amend because Plaintiffs failed to allege a specific link between RG-101, liver toxicity, and the serious adverse events involving jaundice. (ECF No. 32.) Without this link, the Court could not determine the preclinical or nonclinical findings contradicted Defendants’ public statements or made them false or misleading. (Id.) On October 1, 2019, Plaintiffs filed an amended consolidated complaint. (ECF No. 33.) Before Defendants could answer or respond to the amended consolidated complaint, the parties reached a settlement. (ECF 38-2.) The Court denied preliminary approval of the settlement because the release terms were unclear and the notice procedures were deficient. (ECF No. 39.) On February 7, 2020, the parties submitted an amended settlement agreement (“Settlement Agreement”). (ECF No. 40.) The amended settlement agreement defined the “Settlement Class” as: all persons and entities that purchased or otherwise acquired shares of the publicly traded common stock of Regulus during the Class Period who allege to have been damaged thereby. Excluded from the Settlement Class are (i) Defendants; (ii) members of the immediate families of Defendants; (iii) any person who is or was an officer or director of Regulus during or after the Class Period; (iv) any entity in which any of the Defendants had or has a controlling interest; and (v) any legal representatives, agents, affiliates, heirs, beneficiaries, successors-in-interest, or assigns of any such excluded party in their capacity as such. Also excluded from the Settlement Class is any Person who validly requests exclusion pursuant to the requirements set forth in the Notice. (ECF No. 40-2 (“Settlement Agreement”), 11:13–25 (¶ 1.34).) The Class Period “means the period between February 17, 2016 and June 11, 2017, inclusive.” (Id. at 5:14–15 (¶ 1.4).) In its Preliminary Approval Order, the Court conditionally certified the Settlement Class and provisionally appointed Levi & Korsinsky LLP as class counsel and plaintiffs Mark Appel and Michael Spitters as class representative. B. Terms of the Settlement Agreement Under the terms of the Settlement Agreement, Defendants will pay $900,000 into a gross common settlement fund, without admitting liability. (Id. at 11:11–12 (¶ 1.33).) Of the $900,000, the Settlement Class will receive what remains after subtracting the cost of any attorneys’ fees and expenses, notice and administration costs, and Lead Plaintiff's service awards, and applicable taxes (the “Net Settlement Fund”). (Id. at 7:17–20 (¶ 1.18).) The Net Settlement Fund will be distributed among claimants on a pro rata basis based on the Plan of Allocation. (Id. ¶ 1.21.) “The Plan of Allocation generally measures the amount of loss that a Settlement Class member can claim for purposes of making pro rata allocations of the Net Settlement Fund to Settlement Class members who submit valid Proof of Claim and Release forms “Authorized Claimants”). (ECF No. 46-5 (“Class Notice”), at 5 (§ 9).) For each share of Regulus common stock purchased or otherwise acquired during the Class Period, the amount of the claim will be: 2/17/2016- | 6/28/2016- | 7/28/2016- | 1/30/2017 Sold on or

=

6/11/2017 (/d. at 6.) 1. Attorneys’ Fees and Costs Under the Settlement Agreement, Plaintiffs counsel agreed to seek no more 49 than 25 percent of the Settlement Amount, plus no more than $15,000 in litigation costs and expenses. (Settlement Agreement, 23:25—24:10 (J 6.1); Class Notice, 9 (§ 18).) 2. Remainder Any balance remaining in the Settlement Fund six months after the initial distribution shall be redistributed to Authorized Claimants who have cashed their \initial distributions, after payment of any unpaid costs or fees incurred in administering the Setthement Fund for such redistribution if Lead Counsel, in \\consultation with the Claims Administrator, determines that additional redistributions, after deduction of any additional fees and expenses that would be

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Regulus Therapeutics Inc. Securities Litigation, (S.D. Cal. 2020).

In Re Regulus Therapeutics Inc. Securities Litigation (In Re Regulus Therapeutics Inc. Securities Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
In Re Bluetooth Headset Products Liability
654 F.3d 935 (Ninth Circuit, 2011)
Valjeanne Currie v. Group Insurance Commission
290 F.3d 1 (First Circuit, 2002)
Rodriguez v. West Publishing Corp.
563 F.3d 948 (Ninth Circuit, 2009)
In Re Linerboard Antitrust Litigation
321 F. Supp. 2d 619 (E.D. Pennsylvania, 2004)
Maley v. Del Global Technologies Corp.
186 F. Supp. 2d 358 (S.D. New York, 2002)
In Re Tableware Antitrust Litigation
484 F. Supp. 2d 1078 (N.D. California, 2007)
In Re MicroStrategy, Inc. Securities Litigation
148 F. Supp. 2d 654 (E.D. Virginia, 2001)
Andre Martello Barton v. U.S. Attorney General
904 F.3d 1294 (Eleventh Circuit, 2018)
Harris v. Marhoefer
24 F.3d 16 (Ninth Circuit, 1994)
Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)
In re Citigroup Inc. Securities Litigation
965 F. Supp. 2d 369 (S.D. New York, 2013)
Bellinghausen v. Tractor Supply Co.
306 F.R.D. 245 (N.D. California, 2015)
United States v. Perry
559 F. Supp. 19 (E.D. Arkansas, 1982)
Class v. City of Seattle
955 F.2d 1268 (Ninth Circuit, 1992)